NantKwest Inc

NASDAQ:NK   3:03:14 PM EDT
17.14
+0.14 (+0.79%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)1.86B
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$0.01 Million
Adjusted EPS-$0.19
See more estimates
10-Day MA$16.48
50-Day MA$12.07
200-Day MA$9.07
See more pivots

NantKwest, Inc. Stock, NASDAQ:NK

3530 JOHN HOPKINS COURT, SAN DIEGO, CA 92121
United States of America
Phone: (858) 633-0300
Number of Employees: 161

Description

NantKwest, Inc., a clinical-stage immunotherapy biotechnology company, develops immunotherapeutic treatments for cancer, infectious diseases, and inflammatory diseases in the United States. The company develops activated natural killer product candidates for the treatment of virally-induced cancers, such as polyoma virus induced merkel cell carcinoma, human papilloma virus induced cervical, and head and neck cancers; infectious diseases, including Ebola; and other serious viral, fungal, and bacterial infections. It is also develops high-affinity natural killer product candidates primarily for the treatment of solid tumors, breast cancer, head and neck/squamous, lymphoma, and various cancer; and target activated natural killer product candidates to treat hematological malignancies and solid tumors. NantKwest, Inc. has a co-development agreement with Altor Bio Science Corporation to collaborate on the development of therapeutic applications combining the company's proprietary natural killer cells with Altor's ALT-801 and/or ALT-803 products. The company was formerly known as Conkwest, Inc. and changed its name to NantKwest, Inc. in July 2015. NantKwest, Inc. was founded in 2002 and is headquartered in San Diego, California.